LONDON, April 14, 2016 /PRNewswire/ --
Thorn Medical PLC ("Thorn" or the "Company"), the international healthcare group, today announces the acquisition of Okyanos Holding Company Ltd., the leading stem cell therapy centre based in the Bahamas.
Okyanos is fully licensed to provide Stem Cell based treatments for cardiovascular, lung and autoimmune diseases, as well as for orthopedic and urological conditions, neurological disorders and chronic wounds and tissue ischemia.
Jack Kaye, Thorn Medical's Chief Executive, said: "With this acquisition of a controlling stake in Okyanos, we can leverage our own stem cell research and therapy license to start providing immediate treatments for patients, rather than waiting until completion of our own facilities. Okyanos is a Cell Therapy Center of Excellence with a world-class medical and scientific team and have already successfully treated nearly 200 patients, achieving remarkable outcomes and greatly improving their quality of life."
Matthew Feshbach, Chief Executive Officer and Co-Founder of Okyanos, said, "We have developed a world-class facility, medical team and protocols using adipose(fat)- derived stem and regenerative cells (ADRCs) to treat chronic degenerative diseases. We have demonstrated clinically that multiple conditions can respond to Okyanos cell therapy in a single treatment, greatly improving the quality of life for our patients. Our advanced technologies allow us to perform real-time stem cell therapy by harvesting, isolating and returning ADRCs to the same patient in the same day."
Manuel Vianna, Chief Operating Officer and Co-Founder of Okyanos added, "We have very high patient satisfaction and are now ready to rapidly increase patient numbers. We were looking for a partner to help speed up our growth, so are delighted to have joined Thorn Medical's international healthcare group."
As Mr. Kaye summed it up, "Thorn Medical has ambitious plans for growing the company rapidly to become a major international force in the medical and healthcare arena. We plan to leverage the state-of-the-art facilities and expert staff of Okyanos to quickly become the leading human stem cell treatment company in the Western world, so I look forward to welcoming the Okyanos team to the group."
THE DIRECTORS OF THE ISSUER ACCEPT RESPONSIBILITY FOR THE CONTENTS OF THIS ANNOUNCEMENT
Note to Editors
Thorn Medical PLC
Thorn Medical is a trusted expert investor and acceleration partner dedicated to breaking down the barriers to providing more efficient and effective healthcare worldwide.
With a clear focus on improving human wellbeing, it acts as an aggregator of innovative, scientifically-validated medical technology, pharmaceutical products and healthcare services businesses.
It aims to transform organisational performance through delivering best practice flexible management services that streamline operations, reduce costs, encourage cross-fertilisation, expand market reach and enhance return on capital.
Thorn Medical is dedicated to this market, with a global perspective and an understanding at first hand of the evolving challenges that healthcare businesses face in growing successfully.
Thorn Medical understands how to create value for investors, service providers and patients through building a balanced portfolio of pre-and post-revenue companies that specialise in commercialising innovative and medical technologies and services.
Thorn Medical will continue to grow both organically and through acquisitions, continually developing the enterprise and fully addressing the human health cycle and its genetic, environmental, physical and nutritional influencing factors.
Thorn Medical focuses on four areas
- Disease prevention
- Immunity optimisation
- Disease treatment
- Research & development
For further information, please visit Thorn Medical's website http://www.thornmedical.com
Contact: Henry Gewanter, Thorn Medical PLC, Tel: +44(0)7774-228845
